CKD 508
Alternative Names: CKD-508Latest Information Update: 19 Jan 2024
At a glance
- Originator Chong Kun Dang
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 16 Jan 2024 Phase I development is ongoing for Dyslipidaemias (In volunteers) in United Kingdom (PO) (Chong Kun Dang pipeline, January 2024)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in United Kingdom (PO)
- 06 Jul 2020 Phase-I clinical trials in Dyslipidaemias (In volunteers) in United Kingdom (PO, Capsule) (NCT04488900)